首页> 美国卫生研究院文献>Toxicological Sciences >Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea
【2h】

Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea

机译:人类3D胃肠道微组织屏障功能作为药物性腹泻的预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug-induced gastrointestinal toxicities (GITs) rank among the most common clinical side effects. Preclinical efforts to reduce incidence are limited by inadequate predictivity of in vitro assays. Recent breakthroughs in in vitro culture methods support intestinal stem cell maintenance and continual differentiation into the epithelial cell types resident in the intestine. These diverse cells self-assemble into microtissues with in vivo-like architecture. Here, we evaluate human GI microtissues grown in transwell plates that allow apical and/or basolateral drug treatment and 96-well throughput. Evaluation of assay utility focused on predictivity for diarrhea because this adverse effect correlates with intestinal barrier dysfunction which can be measured in GI microtissues using transepithelial electrical resistance (TEER). A validation set of widely prescribed drugs was assembled and tested for effects on TEER. When the resulting TEER inhibition potencies were adjusted for clinical exposure, a threshold was identified that distinguished drugs that induced clinical diarrhea from those that lack this liability. Microtissue TEER assay predictivity was further challenged with a smaller set of drugs whose clinical development was limited by diarrhea that was unexpected based on 1-month animal studies. Microtissue TEER accurately predicted diarrhea for each of these drugs. The label-free nature of TEER enabled repeated quantitation with sufficient precision to develop a mathematical model describing the temporal dynamics of barrier damage and recovery. This human 3D GI microtissue is the first in vitro assay with validated predictivity for diarrhea-inducing drugs. It should provide a platform for lead optimization and offers potential for dose schedule exploration.
机译:药物引起的胃肠道毒性(GIT)属于最常见的临床副作用。减少体外试验的可预测性限制了减少发病率的临床前努力。体外培养方法的最新突破支持肠道干细胞的维持和持续分化为驻留在肠道中的上皮细胞类型。这些不同的细胞自组装成具有体内样结构的微组织。在这里,我们评估了人孔胃肠道微孔板中生长的胃肠道微组织,这些微孔组织允许进行根尖和/或基底外侧药物治疗以及96孔通量。分析实用性的评估侧重于腹泻的可预测性,因为这种不良反应与肠屏障功能障碍有关,可以使用上皮电阻(TEER)在胃肠道微组织中进行测量。组装了一套确认有效的处方药,并测试了其对TEER的影响。当针对临床暴露调整所得的TEER抑制能力时,确定了一个阈值,以将引起临床腹泻的药物与缺乏这种作用的药物区分开。微量药物TEER分析的可预测性受到一小部分药物的挑战,这些药物的临床发展受到腹泻的限制,这是根据1个月的动物研究得出的。微组织TEER可以准确预测每种药物的腹泻情况。 TEER的无标签性质使得能够以足够的精确度进行重复定量,从而开发出描述障碍物破坏和恢复的时间动态的数学模型。这种人类3D GI显微组织是第一个体外验证诱导腹泻药物具有可预测性的体外测定法。它应该为铅优化提供平台,并为剂量计划探索提供潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号